Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Marksans Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Marksans Pharma Limited announces USFDA approval for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg (ANDA 204948)
Marksans Pharma Ltd has informed BSE regarding a Press Release dated October 18, 2016 titled "Marksans Pharma Limited announces USFDA approval for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg (ANDA 204948)". Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Marksans Pharma Ltd has informed BSE regarding the details of Voting results at the 24th Annual General Meeting (AGM) of the Company held on September 29, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report. Outcome of AGM
Marksans Pharma Ltd has informed BSE that the 24th Annual General Meeting (AGM) of the Company was held on September 29, 2016. Despite lower interest & taxation, Marksans Pharma net dips by 26% in 201516
Marksans Pharma, a Rs. 890 crore plus pharma major related to Glenmark Pharmaceuticals, has failed to generate confidence among its investors. Marksans Pharma surges on USFDA nod for Loratadine
The stock rallied 12% to Rs 53.55 after the USFDA approval for loratadine liquid filed capsules 10 mg Marksans Pharma Limited announces USFDA approval for Loratadine Liquid Filled Capsules 10 mg (ANDA 206214)
Marksans Pharma Ltd has informed BSE regarding a Press Release titled "Marksans Pharma Limited announces USFDA approval for Loratadine Liquid Filled Capsules 10 mg (ANDA 206214)". AGM on Sept 29, 2016
Marksans Pharma Ltd has informed BSE that the 24th Annual General Meeting (AGM) of the Company will be held on September 29, 2016. Fixes Book Closure for AGM (Cut-off date for e-voting)
Marksans Pharma Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 24, 2016 to September 29, 2016 (both days inclusive) for the purpose of 24th Annual General Meeting (AGM) of the Company to be held on September 29, 2016.